SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.37+0.9%Dec 8 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9126)9/14/2003 7:46:58 PM
From: Torben Noerup Nielsen   of 52153
 
Now that it is approved, Cubicin doesn't have to beat Vancomycin across the board. It isn't possible to control for everything in a trial. Given the problems we are having with resistance, anything is worth a try.

Using Cubicin while avoiding Vancomycin for a while *might* cause the VR strains to revert and loose resistance.

I've been accumulating this one for a while. I've learned not to ask V1 about it since it has dived every time I've asked :-)

Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News